Resistance to mutant group 2 influenza virus neuraminidases of an oseltamivir-zanamivir hybrid inhibitor

Journal of Virology

Volumn 90, Issue 23, 2016, Pages 10693-10700

  Wu, Yan ^a,f   Gao, Feng ^b   Qi, Jianxun ^a   Bi, Yuhai ^a   Fu, Lifeng ^a   Mohan, Sankar ^c   Chen, Yuhang ^b   Li, Xuebing ^a   Pinto, B Mario ^c   Vavricka, Christopher J ^a   Tien, Po ^a   Gao, George F ^a,d,e  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b INSTITUTE OF GENETICS AND DEVELOPMENTAL BIOLOGY   (China)

^c SIMON FRASER UNIVERSITY   (Canada)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^e INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^f UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN; MS 257; OSELTAMIVIR; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS SIALIDASE; ZANAMIVIR; ANTIVIRUS AGENT; ENZYME INHIBITOR; SIALIDASE; VIRAL PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME INHIBITION; HYDROGEN BOND; HYDROPHOBICITY; INFLUENZA VIRUS; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN MODIFICATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; INFLUENZA A VIRUS; MOLECULAR MODEL; MUTATION;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS; MODELS, MOLECULAR; MUTATION; NEURAMINIDASE; OSELTAMIVIR; VIRAL PROTEINS; ZANAMIVIR;

EID: 85001130797     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01703-16     Document Type: Article

References (54)

1. Krumbholz A, Schmidtke M, Bergmann S, Motzke S, Bauer K, Stech J, Durrwald R, Wutzler P, Zell R. 2009. High prevalence of amantadine resistance among circulating European porcine influenza A viruses. J Gen Virol 90:900-908. http://dx.doi.org/10.1099/vir.2008.007260-0.
2. Deyde V, Garten R, Sheu T, Smith C, Myrick A, Barnes J, Xu X, Shaw M, Klimov A, Gubareva L. 2009. Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006-2008. Influenza Other Respir Viruses 3:297-314. http://dx.doi.org /10.1111/j.1750-2659.2009.00103.x.
3. Deyde VM, Xu X, Bright RA, Shaw M, Smith CB, Zhang Y, Shu Y, Gubareva LV, Cox NJ, Klimov AI. 2007. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 196:249-257. http://dx.doi.org/10.1086/518936.
4. Simonsen L, Viboud C, Grenfell BT, Dushoff J, Jennings L, Smit M, Macken C, Hata M, Gog J, Miller MA, Holmes EC. 2007. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol Biol Evol 24:1811-1820. http://dx.doi.org/10.1093/molbev/msm103.
5. Hurt AC LS, Speers DJ, Barr IG, Maurer-Stroh S. 2012. Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses. Emerg Infect Dis 18:109-112.
6. Seibert CW, Rahmat S, Krammer F, Palese P, Bouvier NM. 2012. Efficient transmission of pandemic H1N1 influenza viruses with highlevel oseltamivir resistance. J Virol 86:5386-5389. http://dx.doi.org/10.1128/JVI.00151-12.
7. Stoner TD, Krauss S, DuBois RM, Negovetich NJ, Stallknecht DE, Senne DA, Gramer MR, Swafford S, DeLiberto T, Govorkova EA, Webster RG. 2010. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype. J Virol 84:9800-9809. http://dx.doi.org/10.1128/JVI.00296-10.
8. Chen H, Cheung CL, Tai H, Zhao P, Chan JF, Cheng VC, Chan KH, Yuen KY. 2009. Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg Infect Dis 15:1970-1972. http://dx.doi.org/10.3201/eid1512.091057.
9. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y, Kawaoka Y. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108. http://dx.doi.org/10.1038/4371108a.
10. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG, Zambon M. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 50:2395-2402. http://dx.doi.org/10.1128/AAC.01339-05.
11. Nguyen HT, Fry AM, Gubareva LV. 2012. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther 17:159-173. http://dx.doi.org/10.3851/IMP2067.
12. Abed Y, Baz M, Boivin G. 2006. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 11:971-976.
13. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, Hay AJ, Gamblin SJ, Skehel JJ. 2006. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443:45-49. http://dx.doi.org/10.1038/nature05114.
14. Li Q, Qi J, Zhang W, Vavricka CJ, Shi Y, Wei J, Feng E, Shen J, Chen J, Liu D, He J, Yan J, Liu H, Jiang H, Teng M, Li X, Gao GF. 2010. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol 17:1266-1268. http://dx.doi.org/10.1038/nsmb.1909.
15. Sun X, Li Q, Wu Y, Wang M, Liu Y, Qi J, Vavricka CJ, Gao GF. 2014. Structure of influenza virus N7: the last piece of the neuraminidase "jigsaw" puzzle. J Virol 88:9197-9207. http://dx.doi.org/10.1128/JVI.00805-14.
16. Wu Y, Qin G, Gao F, Liu Y, Vavricka CJ, Qi J, Jiang H, Yu K, Gao GF. 2013 Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding. Sci Rep 3:1551.
17. Wu Y, Bi Y, Vavricka CJ, Sun X, Zhang Y, Gao F, Zhao M, Xiao H, Qin C, He J, Liu W, Yan J, Qi J, Gao GF. 2013. Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. Cell Res http://dx.doi.org/10.1038/cr.2013.144.
18. Vavricka CJ, Li Q, Wu Y, Qi J, Wang M, Liu Y, Gao F, Liu J, Feng E, He J, Wang J, Liu H, Jiang H, Gao GF. 2011. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. PLoS Pathog 7:e1002249. http: //dx.doi.org/10.1371/journal.ppat.1002249.
19. Wang M, Qi J, Liu Y, Vavricka CJ, Wu Y, Li Q, Gao GF. 2011. Influenza A virus N5 neuraminidase has an extended 150-cavity. J Virol 85:8431-8435 http://dx.doi.org/10.1128/JVI.00638-11.
20. Cox NJ, Subbarao K. 2000. Global epidemiology of influenza: past and present. Annu Rev Med 51:407-421. http://dx.doi.org/10.1146/annurev.med.51.1.407.
21. Centers for Disease Control and Prevention. 2012. Update: influenza A (H3N2)v transmission and guidelines-five states, 2011. MMWR Morb Mortal Wkly Rep 60:1741-1744.
22. Centers for Disease Control and Prevention. 2011. Swine-origin influenza A (H3N2) virus infection in two children-Indiana and Pennsylvania, July-August 2011. MMWR Morb Mortal Wkly Rep 60:1213-1215.
23. Centers for Disease Control and Prevention. 2011. Limited human-tohuman transmission of novel influenza A (H3N2) virus-Iowa, November 2011 MMWR Morb Mortal Wkly Rep 60:1615-1617.
24. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ. 2008. Crystal structures of oseltamivirresistant influenza virus neuraminidase mutants. Nature 453:1258-1261. http://dx.doi.org/10.1038/nature06956.
25. van der Vries E, Collins PJ, Vachieri SG, Xiong X, Liu J, Walker PA, Haire LF, Hay AJ, Schutten M, Osterhaus AD, Martin SR, Boucher CA, Skehel JJ, Gamblin SJ. 2012. H1N1 2009 Pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis. PLoS Pathog 8:e1002914. http://dx.doi.org/10.1371 /journal.ppat.1002914.
26. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, Sheu TG, Xu X, Klimov AI, Gubareva LV. 2010. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother 54:1834-1841. http://dx.doi.org/10.1128/AAC.01608-09.
27. Baz M, Abed Y, McDonald J, Boivin G. 2006. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 43:1555-1561. http://dx.doi.org/10.1086/508777.
28. Barnett JM, Cadman A, Burrell FM, Madar SH, Lewis AP, Tisdale M, Bethell R. 1999. In vitro selection and characterisation of influenza B/Beijing/ 1/87 isolates with altered susceptibility to zanamivir. Virology 265: 286-295. http://dx.doi.org/10.1006/viro.1999.0058.
29. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. 1997. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 71:3385-3390.
30. Blick TJ, Tiong T, Sahasrabudhe A, Varghese JN, Colman PM, Hart GJ, Bethell RC, McKimm-Breschkin JL. 1995. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 214:475-484. http://dx.doi.org/10.1006/viro.1995.0058.
31. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, Ward P. 2001. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 20:127-133. http://dx.doi.org/10.1097 /00006454-200102000-00002.
32. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765. http://dx.doi.org/10.1016/S0140-6736(04)16934-1.
33. Carr J, Ives J, Roberts NA, Tai CY, Mendel DB, Kelly L, Lambkin R, Oxford J. 2000. An oseltamivir treatment-selected influenza A/Wuhan/ 359/95 virus with an E119V mutation in the neuraminidase gene has reduced infectivity in vivo, p 23. In Second International Symposium on Influenza and other Respiratory Viruses. The Macrae Group, New York, NY.
34. Staschke KA, Colacino JM, Baxter AJ, Air GM, Bansal A, Hornback WJ, Munroe JE, Laver WG. 1995. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 214:642-646. http://dx.doi.org/10.1006/viro.1995.0078.
35. Richard M, Ferraris O, Erny A, Barthelemy M, Traversier A, Sabatier M, Hay A, Lin YP, Russell RJ, Lina B. 2011. Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. Antimicrob Agents Chemother 55:2942-2952. http://dx.doi.org/10.1128/AAC.01699-10.
36. Mohan S, McAtamney S, Haselhorst T, von Itzstein M, Pinto BM. 2010. Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of viruslike particles. J Med Chem 53:7377-7391.
37. Niikura M, Bance N, Mohan S, Mario Pinto B. 2011. Replication inhibition activity of carbocycles related to oseltamivir on influenza A virus in vitro. Antiviral Res 90:160-163. http://dx.doi.org/10.1016/j.antiviral.2011.03.180.
38. Kerry PS, Mohan S, Russell RJ, Bance N, Niikura M, Pinto BM. 2013. Structural basis for a class of nanomolar influenza A neuraminidase inhibitors. Sci Rep 3:2871.
39. Albohy A, Mohan S, Zheng RB, Pinto BM, Cairo CW. 2011. Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes. Bioorg Med Chem 19:2817-2822. http://dx.doi.org/10.1016/j.bmc.2011.03.039.
40. Rossmann MG, van Beek CG. 1999. Data processing. Acta Crystallogr D Biol Crystallogr 55:1631-1640. http://dx.doi.org/10.1107/S0907444 999008379.
41. Vagin A, Teplyakov A. 1997. MOLREP: an automated program for molecular replacement. J Appl Crystallogr 30:1022-1025. http://dx.doi.org /10.1107/S0021889897006766.
42. Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53:240-255. http://dx.doi.org/10.1107/S090 7444996012255.
43. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC. 2002 PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr 58:1948-1954 http://dx.doi.org/10.1107/S0907444902016657.
44. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132. http://dx.doi.org/10.1107/S0907444904019158.
45. Laskowski RMM, Moss D, Thornton J. 1993. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26:283-291. http://dx.doi.org/10.1107/S0021889892009944.
46. Gubareva LV, Webster RG, Hayden FG. 2001. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 45:3403-3408. http://dx.doi.org/10.1128/AAC.45.12.3403-3408.2001.
47. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-DN-acetylneuraminate) substrate. Anal Biochem 94:287-296. http://dx.doi.org/10.1016/0003-2697(79)90362-2.
48. Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA. 2008. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol 82: 10493-10501. http://dx.doi.org/10.1128/JVI.00959-08.
49. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Martin SR, Daniels RS, Gregory V, Skehel JJ, Gamblin SJ, Hay AJ. 2009. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 27:6317-6323 http://dx.doi.org/10.1016/j.vaccine.2009.07.017.
50. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. 2001 Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 183:523-531. http://dx.doi.org/10.1086/318537.
51. Dörwald FZ. 2012. Lead optimization for medicinal chemists. Wiley-VCH, Weinheim, Germany.
52. Zhu X, McBride R, Nycholat CM, Yu W, Paulson JC, Wilson IA. 2012. Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic acid receptors. J Virol 86:13371-13383. http://dx.doi.org /10.1128/JVI.01426-12.
53. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV. 2010. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 51:983-984. http: //dx.doi.org/10.1086/656439.
54. Hurt AC, Lee RT, Leang SK, Cui L, Deng YM, Phuah SP, Caldwell N, Freeman K, Komadina N, Smith D, Speers D, Kelso A, Lin RT, Maurer-Stroh S, Barr IG. 2011. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 16(23):pii=19884.